Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

O'Brien S., Jones J. A., Coutre S. E., Mato A. R., Hillmen P., Tam C., ...Daha Fazla

LANCET ONCOLOGY, cilt.17, sa.10, ss.1409-1418, 2016 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 10
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/s1470-2045(16)30212-1
  • Dergi Adı: LANCET ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1409-1418
  • Ankara Üniversitesi Adresli: Evet

Özet

Background The TP53 gene, encoding tumour suppressor protein p53, is located on the short arm of chromosome 17 (17p). Patients with 17p deletion (del17p) chronic lymphocytic leukaemia have poor responses and survival after chemoimmunotherapy. We assessed the activity and safety of ibrutinib, an oral covalent inhibitor of Bruton's tyrosine kinase, in relapsed or refractory patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.